Klingensmith Harvey Robert 4

What Happened

• Harvey Klingensmith, a director of Core Laboratories Inc. (CLB), reported multiple transactions on April 1, 2026: an exercise/conversion of derivative instruments for 8,069 shares (reported as acquired), a grant/award of 7,895 restricted shares (acquired), and a matching disposal/transfer of 8,069 derivative shares. All transactions are reported at $0.00 consideration (total reported value $0).

Key Details

• Transaction date: 2026-04-01; Form 4 filed with accession dated 2026-04-07.
• Reported transactions:
  • M (exercise/conversion): 8,069 shares acquired at $0.00.
  • A (award/grant): 7,895 restricted shares acquired at $0.00 (derivative).
  • M (exercise/conversion): 8,069 shares disposed at $0.00.
• Vesting notes:
  • Footnote F1: The 7,895 restricted shares will vest after a one-year period on April 1, 2027 (subject to plan terms and potential deferral).
  • Footnote F2: A separate set of restricted shares vested on April 1, 2026.
• Shares owned after the reported transactions: not specified in the provided filing excerpt.
• Timeliness: Filing date is 2026-04-07 for transactions dated 2026-04-01. Form 4s are typically due within two business days of the transaction; check the full filing for any late-filing notation.

Context

• Codes: "M" indicates exercise/conversion of a derivative (e.g., option/phantom/unit) and "A" indicates an award/grant of shares. Here, the filing shows both an acquisition via grant and conversion/exercise with a simultaneous disposal of the same 8,069 units, all at $0.00 consideration.
• Interpretation for retail investors: Awards and vested restricted shares are common director compensation and do not necessarily signal a buy/sell view on the market. Purchases (cash outlay) are generally stronger bullish signals; these transactions appear to be plan-related conversions/vestings rather than open-market trades.